% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Reinhardt:147394,
      author       = {A. Reinhardt$^*$ and D. Stichel$^*$ and D. Schrimpf$^*$ and
                      C. Koelsche$^*$ and A. K. Wefers$^*$ and A. Ebrahimi$^*$ and
                      P. Sievers$^*$ and K. Huang$^*$ and M. B. Casalini$^*$ and
                      F. Fernández-Klett$^*$ and A. Suwala$^*$ and M. Weller and
                      D. Gramatzki and J. Felsberg and G. Reifenberger$^*$ and A.
                      Becker and V. H. Hans and M. Prinz and O. Staszewski and T.
                      Acker and H. Dohmen and C. Hartmann and W. Paulus and K.
                      Heß and B. Brokinkel and J. Schittenhelm and R. Buslei and
                      M. Deckert and C. Mawrin and E. Hewer and U. Pohl and Z.
                      Jaunmuktane and S. Brandner and A. Unterberg and D. Hänggi
                      and M. Platten$^*$ and S. M. Pfister$^*$ and W. Wick and C.
                      Herold-Mende and A. Korshunov$^*$ and D. E. Reuss$^*$ and F.
                      Sahm$^*$ and D. T. W. Jones$^*$ and D. Capper$^*$ and A. von
                      Deimling$^*$},
      title        = {{T}umors diagnosed as cerebellar glioblastoma comprise
                      distinct molecular entities.},
      journal      = {Acta Neuropathologica Communications},
      volume       = {7},
      number       = {1},
      issn         = {2051-5960},
      address      = {London},
      publisher    = {Biomed Central},
      reportid     = {DKFZ-2019-02511},
      pages        = {163},
      year         = {2019},
      note         = {EA:B300LA:B300},
      abstract     = {In this multi-institutional study we compiled a
                      retrospective cohort of 86 posterior fossa tumors having
                      received the diagnosis of cerebellar glioblastoma (cGBM).
                      All tumors were reviewed histologically and subjected to
                      array-based methylation analysis followed by algorithm-based
                      classification into distinct methylation classes (MCs). The
                      single MC containing the largest proportion of 25 tumors
                      diagnosed as cGBM was MC anaplastic astrocytoma with piloid
                      features representing a recently-described molecular tumor
                      entity not yet included in the WHO Classification of Tumours
                      of the Central Nervous System (WHO classification).
                      Twenty-nine tumors molecularly corresponded to either of 6
                      methylation subclasses subsumed in the MC family GBM IDH
                      wildtype. Further we identified 6 tumors belonging to the MC
                      diffuse midline glioma H3 K27 M mutant and 6 tumors
                      allotted to the MC IDH mutant glioma subclass astrocytoma.
                      Two tumors were classified as MC pilocytic astrocytoma of
                      the posterior fossa, one as MC CNS high grade
                      neuroepithelial tumor with BCOR alteration and one as MC
                      control tissue, inflammatory tumor microenvironment. The
                      methylation profiles of 16 tumors could not clearly be
                      assigned to one distinct MC. In comparison to supratentorial
                      localization, the MC GBM IDH wildtype subclass midline was
                      overrepresented, whereas the MCs GBM IDH wildtype subclass
                      mesenchymal and subclass RTK II were underrepresented in the
                      cerebellum. Based on the integration of molecular and
                      histological findings all tumors received an integrated
                      diagnosis in line with the WHO classification 2016. In
                      conclusion, cGBM does not represent a molecularly uniform
                      tumor entity, but rather comprises different brain tumor
                      entities with diverse prognosis and therapeutic options.
                      Distinction of these molecular tumor classes requires
                      molecular analysis. More than $30\%$ of tumors diagnosed as
                      cGBM belong to the recently described molecular entity of
                      anaplastic astrocytoma with piloid features.},
      cin          = {B300 / B360 / L101 / L401 / L601 / L201},
      ddc          = {610},
      cid          = {I:(DE-He78)B300-20160331 / I:(DE-He78)B360-20160331 /
                      I:(DE-He78)L101-20160331 / I:(DE-He78)L401-20160331 /
                      I:(DE-He78)L601-20160331 / I:(DE-He78)L201-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31661039},
      pmc          = {pmc:PMC6816155},
      doi          = {10.1186/s40478-019-0801-8},
      url          = {https://inrepo02.dkfz.de/record/147394},
}